To test this prediction, we treated colon adenocarcinoma cell line RKO cells with a lower IGF2BP3 level with 3-deazaadenosine (DAA), an inhibitor of internal N6-methyladenosine [19]. This evidence concerns the gene IGF2BP3 and colon adenocarcinoma.